Public Health

The role of genomic screening in transforming public health

Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.

South Australia prioritises preventive health

On 28th November 2024, the SA Parliament passed legislation to make preventive health a key part of South Australian health system for the first time, through a new agency aptly named Preventive Health SA.

Preventive Health SA will lead evidence-informed and innovative action to prevent and reduce the burden of non-communicable health conditions and improve health equity across the South Australia population.

Contrasting Population Needs and Alternative Funding Models

Dr Jaspreet Saini is a GP with a decade of experience, practicing in West Pennant Hills and Rooty Hill, New South Wales. He began his medical journey at Monash University, followed by internships and residency at Blacktown Hospital, in Western Sydney. Instead of confining himself to a single specialty, he pursued general practice to explore various facets of medicine.

Foundation outlines breast cancer research strategy

Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.

Forum fosters dialogue in breast cancer

In October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT and The University of Queensland Faculty of Medicine/Frazer Institute.

The key aim of the event co-organised by Associate Professor Joy Wolfram, Group Leader, Australian Institute for Bioengineering and Nanotechnology & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians.

WA and QLD RSV Immunisation programs show drops in infant hospitalisations

RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.

Scroll to top